Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019
Author:
Affiliation:
1. Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital
Publisher
Medical Association of Nippon Medical School
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jnms/88/6/88_JNMS.2022_89-104/_pdf
Reference24 articles.
1. 1. Takemoto Y, Tanaka S, Tanabe J, Nakamura Y, Kohama A, Shibata S. Studies on the effects of primary therapy for DIC following circulatory arrest. Am J Hematol. 1986 Apr;21 (4):377-82.
2. 2. Minakata D, Fujiwara SI, Ikeda T, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019 Feb;109 (2):141-6.
3. 3. Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, Drosten C, Pohlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. antimicrob agents chemother [Internet]. 2020 May 21;64 (6):e00754-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32312781
4. 4. Jang S, Rhee JY. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis [Internet]. 2020 Jul;96:500-2. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32470602
5. 5. Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020 Jul 3;24 (1):392.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration;PLOS ONE;2024-03-22
2. Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019;Journal of Nippon Medical School;2023-10-25
3. Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate;YAKUGAKU ZASSHI;2023-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3